Ticker

No recent analyst price targets found for TRCK.

Latest News for TRCK

IYRI: Covered Call REIT ETF, Strong Distribution Yield, Short, Adequate Track-Record

Neos is an investment manager with several strong, high-growth covered call ETFs. IYRI is one such ETF, focusing on REITs. It has similar characteristics to most covered call ETFs, namely a strong distribution yield, currently reaching 10.9%, but below-average potential capital gains. It's a young fund, with inception in early 2025, and has performed adequately since.

Seeking Alpha • Apr 17, 2026
Financial Survey: SecureAlert (OTCMKTS:TRCK) vs. CoStar Group (NASDAQ:CSGP)

CoStar Group (NASDAQ: CSGP - Get Free Report) and SecureAlert (OTCMKTS:TRCK - Get Free Report) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership. Volatility and Risk CoStar Group has a

Defense World • Apr 17, 2026
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for…

GlobeNewsWire • Apr 15, 2026
Bunker Hill on Track for June Restart. Provides Corporate Update and Commissioning Progress

KELLOGG, Idaho and VANCOUVER, British Columbia, April 15, 2026 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX: BNKR | OTCQB: BHLL) is pleased to provide a corporate update highlighting continued and safe progress toward the restart of the Bunker Hill Mine (the “Project”) in Idaho's Silver Valley anticipated in June 2026.

GlobeNewsWire • Apr 15, 2026
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the first interim analysis results of the Phase 2 B-SUPREME study of pevifoscorvir sodium in participants with chronic hepatitis B virus (HBV)…

GlobeNewsWire • Apr 14, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for TRCK.

No House trades found for TRCK.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top